BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36564761)

  • 1. Increased HRD score in cisplatin resistant penile cancer cells.
    Winkelmann R; Bankov K; Döring C; Cinatl J; Grothe S; Rothweiler F; Michaelis M; Schmitt C; Wild PJ; Demes M; Cinatl J; Vallo S
    BMC Cancer; 2022 Dec; 22(1):1352. PubMed ID: 36564761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
    Zhan M; Liu X
    Chin Med J (Engl); 1999 Apr; 112(4):336-9. PubMed ID: 11593534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.
    Hayashi M; Kawakubo H; Fukuda K; Mayanagi S; Nakamura R; Suda K; Hayashida T; Wada N; Kitagawa Y
    J Gene Med; 2019 Dec; 21(12):e3135. PubMed ID: 31656051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin.
    Merlos Rodrigo MA; Buchtelova H; de Los Rios V; Casal JI; Eckschlager T; Hrabeta J; Belhajova M; Heger Z; Adam V
    J Proteome Res; 2019 Mar; 18(3):1255-1263. PubMed ID: 30592607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
    Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of cisplatin treatment.
    Cho H; Imada T; Oshima T; Shiozawa M; Rino Y; Takanashi Y
    Gastric Cancer; 2002; 5(1):43-6. PubMed ID: 12021859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
    Bedrnicek J; Vicha A; Jarosova M; Holzerova M; Cinatl J; Michaelis M; Cinatl J; Eckschlager T
    Neoplasma; 2005; 52(5):415-9. PubMed ID: 16151587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
    Chen XX; Lai MD; Zhang YL; Huang Q
    World J Gastroenterol; 2002 Oct; 8(5):841-6. PubMed ID: 12378627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
    Blaheta RA; Michaelis M; Natsheh I; Hasenberg C; Weich E; Relja B; Jonas D; Doerr HW; Cinatl J
    Br J Cancer; 2007 Jun; 96(11):1699-706. PubMed ID: 17505515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway.
    Takizawa K; Kamijo R; Ito D; Hatori M; Sumitani K; Nagumo M
    Br J Cancer; 1999 Jun; 80(7):954-63. PubMed ID: 10362102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
    Mizutani Y; Wu XX; Yoshida O; Shirasaka T; Bonavida B
    Oncol Rep; 1999; 6(5):979-82. PubMed ID: 10425290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells.
    Rodrigo MAM; Buchtelova H; Jimenez AMJ; Adam P; Babula P; Heger Z; Adam V
    Cells; 2019 Mar; 8(3):. PubMed ID: 30871063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs.
    Matsuhashi N; Saio M; Matsuo A; Sugiyama Y; Saji S
    Oncol Rep; 2005 Sep; 14(3):609-15. PubMed ID: 16077963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fundamental study of combination chemotherapy with THP, 5-FU and CDDP for human KB carcinoma cell line and its multidrug resistant cell line KB-C1--usefulness of treatment with 5-FU preceding CDDP].
    Kishimoto H; Manno Y; Tanaka H; Moridera K; Urade M
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):505-9. PubMed ID: 11329785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
    Najafzadeh N; Mazani M; Abbasi A; Farassati F; Amani M
    Biomed Pharmacother; 2015 Aug; 74():243-51. PubMed ID: 26349992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line.
    Esaki T; Nakano S; Masumoto N; Fujishima H; Niho Y
    Int J Cancer; 1996 Feb; 65(4):479-84. PubMed ID: 8621231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.
    Johnston PG; Geoffrey F; Drake J; Voeller D; Grem JL; Allegra CJ
    Eur J Cancer; 1996 Nov; 32A(12):2148-54. PubMed ID: 9014759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.
    Etienne MC; Bernard S; Fischel JL; Formento P; Gioanni J; Santini J; Demard F; Schneider M; Milano G
    Br J Cancer; 1991 Mar; 63(3):372-7. PubMed ID: 2003979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
    Michaelis M; Rothweiler F; Barth S; Cinatl J; van Rikxoort M; Löschmann N; Voges Y; Breitling R; von Deimling A; Rödel F; Weber K; Fehse B; Mack E; Stiewe T; Doerr HW; Speidel D; Cinatl J
    Cell Death Dis; 2011 Dec; 2(12):e243. PubMed ID: 22170099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.